TNFSF10 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29363934	1.00	2/20
SCHEMBL8961804	0.69	2/20
SCHEMBL6285363	0.44	2/20
SCHEMBL6309967	0.59	1/20
SCHEMBL28827856	0.58	1/20
SCHEMBL25439856	0.57	1/20
SCHEMBL29769219	0.53	1/20
SCHEMBL4110171	0.51	1/20
SCHEMBL1257981	0.50	1/20
SCHEMBL1409329	0.50	1/20
SCHEMBL7811229	0.50	1/20
SCHEMBL13828967	0.50	1/20
SCHEMBL21398157	0.50	1/20
SCHEMBL28827853	0.50	1/20
SCHEMBL629172	0.49	1/20
SCHEMBL10559120	0.49	1/20
SCHEMBL5592998	0.49	1/20
SCHEMBL10846356	0.48	1/20
SCHEMBL11337650	0.48	1/20
SCHEMBL25604007	0.47	1/20

Clinical trials — most relevant to TNFSF10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes	PHASE4	COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)	PHASE3	COMPLETED
TNFSF11 Inhibition and Fertility: a Prospective Study	PHASE2	COMPLETED
NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
NAPO - Novel Approach for Oligospermia	PHASE1/PHASE2	COMPLETED
FITMI - First In Treating Male Infertility	PHASE2	ACTIVE_NOT_RECRUITING
Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)	PHASE2	COMPLETED
Etanercept in Hidradenitis Suppurativa	PHASE2	COMPLETED
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma	PHASE1/PHASE2	RECRUITING
Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein	PHASE1	COMPLETED
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)	PHASE1	COMPLETED
Phase I Study of APX005M in Pediatric Central Nervous System Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Presurgical Trial of Denosumab in Breast Cancer	EARLY_PHASE1	COMPLETED
Evaluation of Salivary Biomarker Levels in Individuals With Different Periodontal Conditions	nan	COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Effect of Smoking on Periodontal Therapy in Periodontitis	nan	COMPLETED
Decoy Receptor 3 (DcR3) Polymorphisms in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)	nan	UNKNOWN
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS	nan	COMPLETED
Er,Cr:YSGG Laser Application in Peri-implantitis	nan	COMPLETED
Differential Expression of CD200 in B-chronic Lymphoproliferative Disorders by Multicolour Flow Cytometry	nan	UNKNOWN
TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP)	nan	NOT_YET_RECRUITING
NCF Gene & TNFSF4 in SLE Patients	nan	UNKNOWN
Exercise and the Receptor for Advanced Glycation End Products (RAGE)	nan	COMPLETED
Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers	nan	UNKNOWN
Immune Checkpoints in Predicting Response to Neoadjuvant Therapy in Rectal Cancer	nan	COMPLETED
Point of Care Test of LTA Level in Tear Fluid, Measured With a POCT Test, in DE Patients Following IPL Treatment	nan	UNKNOWN
OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism	nan	COMPLETED
The Effect Of Vertical Releasing Incision On Implant Procedures	nan	COMPLETED
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TNFSF10 binder may also engage these)

Protein	Name	Similarity
P50592	—	1.000	P50592 →
Q9BEA1	—	0.994	Q9BEA1 →
Q9Z2V2	—	0.993	Q9Z2V2 →
P36939	—	0.992	P36939 →
P63305	—	0.992	P63305 →
Q9I8D8	—	0.992	Q9I8D8 →
P51749	—	0.992	P51749 →
P27548	—	0.992	P27548 →
Q9BDN3	—	0.991	Q9BDN3 →
Q9BDM3	—	0.991	Q9BDM3 →
P06804	—	0.990	P06804 →
Q95MQ5	—	0.990	Q95MQ5 →
O77764	—	0.990	O77764 →
O97605	—	0.990	O97605 →
P23563	—	0.989	P23563 →
P23383	—	0.989	P23383 →
P59693	—	0.988	P59693 →
CD40LG	CD40 ligand	0.988	landscape →
P41047	—	0.988	P41047 →
P63304	—	0.987	P63304 →
Q5UBV8	—	0.987	Q5UBV8 →
Q539C2	—	0.986	Q539C2 →
P13296	—	0.986	P13296 →
TNF	Tumor necrosis factor	0.986	landscape →
P59695	—	0.986	P59695 →
Q9BDM7	—	0.986	Q9BDM7 →
P36940	—	0.986	P36940 →
P19101	—	0.985	P19101 →
P29553	—	0.985	P29553 →
P59694	—	0.985	P59694 →